ICH E3 calls for narrative descriptions for deaths, other serious adverse events, and selected other significant adverse events when needed to understand the clinical course and relationship to study treatment. Narratives are not required for every participant or every event. Follow the applicable CSR/regulatory criteria for which cases warrant narrative treatment and protect personal information appropriately.
ReviewedEvidence1 sourceSectionWriting & Style
Quick answer
Patient narratives in a Clinical Study Report give a concise chronological account of selected clinically important cases so reviewers can understand what happened and how it was assessed.
Key details
Core IssueICH E3 calls for narrative descriptions for deaths, other serious adverse events, and selected other significant adverse events when needed to understand the clinical course and relationship to study treatment.
Registerscholarly, professional, or research/report writing
Important caveats
Scope Boundary
Narratives are not required for every participant or every event. Follow the applicable CSR/regulatory criteria for which cases warrant narrative treatment and protect personal information appropriately.
Further guidance
Content
Include the case facts needed to follow timing, treatment/exposure, event course, relevant investigations, actions taken, outcome, and assessment, while avoiding irrelevant detail.
Purpose
Patient narratives in a Clinical Study Report give a concise chronological account of selected clinically important cases so reviewers can understand what happened and how it was assessed.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
ICH E3 section 11.4.6 identifies by-patient displays as a distinct part of efficacy evaluation for showing individual response information when useful. A by-patient efficacy display is not the same as the appendix listing of adverse events or a narrative case report; keep efficacy and safety purposes distinct.
ICH E3 section 12.4.2.2 calls for analysis of individual patient laboratory changes by treatment group and gives several possible display approaches. This subsection focuses on within-patient change; it is distinct from group-level values-over-time summaries and from the raw measurement listing.
ICH E3 uses appendices for individual-patient data listings that support critical analyses, including specified listings for disposition, deviations, demographics, efficacy, adverse events, and laboratory measurements. The exact listings and submission format can depend on the reviewing authority; this page is about the ICH E3 report function, not a universal requirement to publish raw patient data publicly.
ICH E3 section 9.4.5 addresses rules or methods used to select the dose and timing of dose for individual patients. This is the patient-level dosing procedure subsection, not the preceding rationale for selecting the study doses or the later results analysis of dose-response relationships.
ICH E3 distinguishes specified patient listings in Appendix 16.2 from all individual-patient archival listings requested only in the United States under Appendix 16.4. The Appendix 16.4 archival-listing statement is explicitly U.S.-specific in ICH E3 and should not be generalized to every ICH region.
ICH E3 section 12.4.1 points to a by-patient listing of abnormal laboratory values in section 14.3.4 and distinguishes that safety display from the broader listing of individual laboratory measurements. This page is about the dedicated abnormal-value listing under ICH E3 14.3.4; it is distinct from the full individual-measurement appendix under 16.2.8 and from analytical discussion in section 12.4.2.
ICH E3 section 11.4.2.7 identifies special efficacy-analysis considerations for active-control studies intended to support equivalence. This is a CSR efficacy-results reporting issue for active-control equivalence designs; it does not define a universal equivalence margin or replace protocol-level design justification.
ICH E3 section 11.4.2.1 calls for covariate or prognostic-factor selection and adjustment to be explained, including adjustment methods, analysis results, supportive statistical documentation, and differences from planned analyses when relevant. This results-stage statistical issue is narrower than the general statistical-methods section and should not be used as a substitute for documenting the full analysis plan.
